Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector newsTweets 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
04/29 ZEALAND PHARMA AKTIESELSKABET : reports Q1 2017 royalty revenue
04/29 SANOFI : Evidation Health Secures Financing From Sanofi-Genzyme BioVentures to F..
04/28 SANOFI SA (NYSE : SNY) reported earnings of $1.42 per share beating Walls Street..
04/28 SANOFI : beats 1Q profit forecasts
04/28 SANOFI : and Regeneron receive CHMP positive opinion for rheumatoid arthritis tr..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/28 SANOFI : Delivers Robust Q1 2017 Financial Results
04/28 SANOFI : Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Ap..
04/28 SANOFI : and Regeneron Announce Kevzara® (sarilumab) Biologics License Applicati..
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
04/27DJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 SNIPPETS ROUNDUP : Sanofi Diabetes Disappointment, And Amgen Pullback Signals CG..
04/28 Sanofi SA (SNY) CEO Olivier Brandicourt on Q1 2017 Results - Earnings Call Tr..
04/28 Sanofi 2017 Q1 - Results - Earnings Call Slides
04/28 FDA accepts sarilumab BLA resubmission, action date May 22
04/28 Sanofi Q1 top line up 11%; earnings up 425% on sale of animal heath unit; sha..
Financials (€)
Sales 2017 36 455 M
EBIT 2017 9 316 M
Net income 2017 6 663 M
Debt 2017 4 680 M
Yield 2017 3,51%
P/E ratio 2017 16,71
P/E ratio 2018 17,91
EV / Sales 2017 3,20x
EV / Sales 2018 3,06x
Capitalization 111 902 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 83,5 €
Spread / Average Target -3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI12.63%121 897
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.31%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results